| P50 | author | Nita K. Patel | Q87989050 |
| | Gale Smith | Q106408037 |
| P2093 | author name string | Hanxin Lu | |
| | Ye Liu | |
| | Gregory Glenn | |
| | Pedro A Piedra | |
| | Brian E Gilbert | |
| | Larry Ellingsworth | |
| | Mimi Guebre-Xabier | |
| P2860 | cites work | Two distinct subtypes of human respiratory syncytial virus | Q45848624 |
| | Removal of the N-Glycosylation Sequon at Position N116 Located in p27 of the Respiratory Syncytial Virus Fusion Protein Elicits Enhanced Antibody Responses after DNA Immunization | Q58780345 |
| | Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein | Q27335061 |
| | Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers | Q27667876 |
| | Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes | Q27668015 |
| | Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody | Q27677570 |
| | Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults | Q33555911 |
| | Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure | Q33744060 |
| | A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein | Q33775790 |
| | Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion | Q33934074 |
| | A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism | Q34492100 |
| | Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats | Q34506016 |
| | Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab | Q34772752 |
| | Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010. | Q35845854 |
| | Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins | Q35995788 |
| | Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. | Q36348462 |
| | Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein | Q37732535 |
| | Gene sequence variability of the three surface proteins of human respiratory syncytial virus (HRSV) in Texas | Q38267482 |
| | Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. | Q38394731 |
| | Molecular epidemiology and molecular characterization of respiratory syncytial viruses at a tertiary care university hospital in Catalonia (Spain) during the 2013-2014 season. | Q39018825 |
| | Neutralizing epitopes of RSV and palivizumab resistance in Japan | Q40059727 |
| | Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract | Q40158643 |
| | A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. | Q40173489 |
| | Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants | Q40528265 |
| | Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats | Q40588255 |
| | Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein | Q40983230 |
| | A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. | Q41060727 |
| | Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs | Q41441320 |
| | Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon | Q41519402 |
| | An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization | Q41721418 |
| | In vivo selection of respiratory syncytial viruses resistant to palivizumab | Q41891744 |
| | ICTV Virus Taxonomy Profile: Pneumoviridae | Q45325475 |
| | Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab | Q45360940 |
| | Palivizumab-resistant human respiratory syncytial virus infection in infancy | Q45375472 |
| | Thermostability of the human respiratory syncytial virus fusion protein before and after activation: implications for the membrane-fusion mechanism | Q45548739 |
| | Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants | Q45553883 |
| | Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community | Q45753705 |
| | Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus | Q45759631 |
| | Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies | Q45844409 |
| P433 | issue | 52 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanoparticle | Q61231 |
| P304 | page(s) | 8069-8078 | |
| P577 | publication date | 2018-10-30 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge | |
| P478 | volume | 36 | |